Amyris Inc. (AMRSQ)

May 7, 2024 - AMRSQ was delisted (reason: shares cancelled)
0.0020
0.00 (0.00%)
Inactive · Last trade price on May 7, 2024
-99.74%
Market Cap 1.48M
Revenue (ttm) 268.22M
Net Income (ttm) -614.55M
Shares Out n/a
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,302
Open 0.0020
Previous Close 0.0020
Day's Range 0.0020 - 0.0020
52-Week Range n/a
Beta 1.12
Analysts n/a
Price Target n/a
Earnings Date n/a

About AMRSQ

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripe... [Read more]

Sector Materials
IPO Date Sep 28, 2010
Employees 1,598
Stock Exchange OTCMKTS
Ticker Symbol AMRSQ
Full Company Profile

Financial Performance

In 2022, Amyris's revenue was $269.85 million, a decrease of -21.06% compared to the previous year's $341.82 million. Losses were -$528.51 million, 95.4% more than in 2021.

Financial Statements

News

Retail investors flock to penny stocks WeWork, Amyris, Proterra

WeWork, a prized startup just four years ago but now a micro-cap, and other penny stocks such as Amyris and Proterra are the latest focus of speculative bets from retail traders, with shares of the fi...

1 year ago - Reuters

Biotech Company Amyris Files for Bankruptcy

Synthetic biotechnology company Amyris filed for Chapter 11 bankruptcy protection as it restructures, leading its share price to drop more than 70% in early trading Thursday.

1 year ago - Investopedia

AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION

Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif...

1 year ago - PRNewsWire

Amyris Warns Of Potential Bankruptcy - Sell

Cash-strapped specialty renewable products developer Amyris remains on life support by largest shareholder and creditor John Doerr. In recent months, Doerr has provided another $157.5 million in secur...

1 year ago - Seeking Alpha

Amyris: CEO's Exit Has Negative Implications

The resignation of Amyris' CEO is likely to be viewed as a positive by many, but the implications of this are negative. Management turnover and the engagement of a consulting firm are not signs of a h...

1 year ago - Seeking Alpha

Amyris: Company Separates From Long-Standing CEO Amid Ongoing Restructuring Efforts - Sell

Earlier this month, cash-strapped specialty renewable products developer Amyris announced a strategic transformation program to improve the company's cost and capital structure and liquidity. Secured ...

1 year ago - Seeking Alpha

AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

EMERYVILLE, Calif. , June 26, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

1 year ago - PRNewsWire

AMYRIS INITIATES STRATEGIC TRANSFORMATION PROGRAM AND SECURES FUNDING

EMERYVILLE, Calif. , June 5, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

1 year ago - PRNewsWire

AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE

EMERYVILLE, Calif. , May 19, 2023 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ techn...

1 year ago - PRNewsWire

Amyris, Inc. (AMRS) Q1 2023 Earnings Call Transcript

Amyris, Inc. (NASDAQ:AMRS) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants John Melo - President and CEO Han Kieftenbeld - CFO Eduardo Alvarez - COO Conference Call Partic...

1 year ago - Seeking Alpha

AMYRIS, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

Core revenue of $56.1 million exceeded Q1 guidance of $49.9 million Cash operating expense down 4% compared to Q1 2022 and down 24% versus Q4 2022 Completed strategic partnership with Givaudan on Apri...

1 year ago - PRNewsWire

AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9

EMERYVILLE, Calif. , May 2, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-t...

1 year ago - PRNewsWire

Top 5 Materials Stocks That May Explode In May - Amyris (NASDAQ:AMRS), MP Materials (NYSE:MP)

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.

Other symbols: MPSXCTRSVHI
1 year ago - Benzinga

AMYRIS REPORTS Q1 2023 REVENUE

EMERYVILLE, Calif. , April 24, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its La...

1 year ago - PRNewsWire

Amyris: Sub-Scale With High Fixed Costs And Limited Growth

Amyris: Sub-Scale With High Fixed Costs And Limited Growth

1 year ago - Seeking Alpha

AMYRIS CLOSES STRATEGIC TRANSACTION WITH GIVAUDAN

Leveraging Amyris' industry-leading biotechnology platform in Beauty for the development and supply of clean sustainable ingredients EMERYVILLE, Calif. , April 5, 2023 /PRNewswire/ -- Amyris, Inc. (Na...

1 year ago - PRNewsWire

Amyris, Inc. (AMRS) Q4 2022 Earnings Call Transcript

Amyris, Inc. (NASDAQ:AMRS) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Han Kieftenbeld - Chief Financial Officer John Melo - President and Chief Executive Officer ...

1 year ago - Seeking Alpha

AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior year Full year Consumer revenue...

1 year ago - PRNewsWire

AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023

EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

1 year ago - PRNewsWire

GIVAUDAN TO ACQUIRE PORTFOLIO OF MAJOR COSMETIC INGREDIENTS FROM AMYRIS AND TO ESTABLISH STRATEGIC PARTNERSHIP FOR NATURAL, SUSTAINABLY SOURCED INGREDIENTS FOR THE BEAUTY INDUSTRY

The bio-based sustainable blockbuster ingredients Squalane, Hemisqualane and Cleanscreen as well as development of future cosmetic ingredients from Amyris will accelerate both companies' leadership in...

1 year ago - PRNewsWire

AMYRIS LAUNCHES 4U BY TIA™ HAIRCARE LINE EXCLUSIVELY AT WALMART

EMERYVILLE, Calif. , Jan. 30, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

2 years ago - PRNewsWire

Amyris: Darkest Before The Dawn

Uncertainty still surrounds the strategic transaction, but it is still likely to close in the coming weeks. Amyris' cash flow problems are improving rapidly, but a large amount of outside cash will li...

2 years ago - Seeking Alpha

AMYRIS TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTH CARE CONFERENCE

EMERYVILLE, Calif. , Jan. 4, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

2 years ago - PRNewsWire

AMYRIS ANNOUNCES $50 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT

EMERYVILLE, Calif. , Dec. 29, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab...

2 years ago - PRNewsWire

AMYRIS SUCCESSFULLY ADVANCES STRATEGIC TRANSACTION

EMERYVILLE, Calif., Dec. 27, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-...

2 years ago - PRNewsWire